BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Dolutegravir/Lamivudine

Patients Co-Infectied with Heptatis B Virus (HBV) & Human Immunodeficiency Virus (HIV-1);

Emergence of Lamivudine-Resistant HBV & Exacerbations of HBV

  • All patients with HIV-1 should be tested for the presence of HBV prior to or when initiating DOVATO. Emergence of lamivudine-resistant HBV variants associated with lamivudine-containing antiretroviral regimens has been reported. If DOVATO is used in patients co-infected with HIV-1 and HBV, additional treatment should be considered for appropriate treatment of chronic HBV; otherwise, consider an alternative regimen.
  • Severe acute exacerbations of HBV have been reported in patients who are co-infected with HIV-1 and HBV and have discontinued lamivudine, a component of DOVATO. Closely monitor hepatic function in these patients and, if appropriate, initiate anti-HBV treatment¬†[see Warnings and Precautions¬†

Patient Counseling Information

Package Inserts

Dolutegravir-Lamivudine

Updated April 2019